The Goldman Sachs Group Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price raised by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on ALNY. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. UBS Group upped their price objective on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Barclays raised their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Finally, Raymond James Financial started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price target on the stock. Twenty-four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $426.85.

Alnylam Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ ALNY opened at $461.24 on Tuesday. The company has a market cap of $60.46 billion, a P/E ratio of -186.74 and a beta of 0.32. The firm has a 50-day simple moving average of $407.07 and a two-hundred day simple moving average of $320.39. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $484.21. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same period last year, the company posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Colleen F. Reitan sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the transaction, the director owned 775 shares of the company’s stock, valued at $362,390. This trade represents a 95.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the completion of the transaction, the executive vice president directly owned 50,121 shares of the company’s stock, valued at $22,718,345.67. This represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 75,594 shares of company stock worth $33,968,256 over the last three months. 1.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Atlantic Union Bankshares Corp purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $30,000. SVB Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth $27,000. Whipplewood Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 71 shares during the last quarter. Bessemer Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $37,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.